Literature DB >> 31369095

Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report.

Enrico Maria Trecarichi1, Angela Quirino2, Vincenzo Scaglione1, Federico Longhini3, Eugenio Garofalo3, Andrea Bruni3, Eugenio Biamonte3, Rosaria Lionello1, Francesca Serapide1, Maria Mazzitelli1, Nadia Marascio2, Giovanni Matera2, Maria Carla Liberto2, Paolo Navalesi3, Carlo Torti1.   

Abstract

Entities:  

Year:  2019        PMID： 31369095     DOI： 10.1093/jac/dkz318

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  18 in total

1.  Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient.

Authors:  Zain I Alamarat; Jessica Babic; Truc T Tran; Susan H Wootton; An Q Dinh; William R Miller; Blake Hanson; Audrey Wanger; Joshua L Gary; Cesar A Arias; Norma Pérez
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 2.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

3.  Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?

Authors:  Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 4.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

5.  Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

Authors:  Mercedes Delgado-Valverde; M Del Carmen Conejo; Lara Serrano; Felipe Fernández-Cuenca; Álvaro Pascual
Journal:  J Antimicrob Chemother       Date:  2020-07-01       Impact factor: 5.790

6.  Cefiderocol for treatment of an empyema due to extensively drug-resistant Pseudomonas aeruginosa: Clinical observations and susceptibility testing considerations.

Authors:  Wesley D Kufel; Jeffrey M Steele; Scott W Riddell; Zachary Jones; Pegah Shakeraneh; Timothy P Endy
Journal:  IDCases       Date:  2020-06-03

Review 7.  Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data.

Authors:  Daniele Roberto Giacobbe; Eugenio Ciacco; Corrado Girmenia; Federico Pea; Gian Maria Rossolini; Giovanni Sotgiu; Carlo Tascini; Mario Tumbarello; Pierluigi Viale; Matteo Bassetti
Journal:  Infect Drug Resist       Date:  2020-12-29       Impact factor: 4.003

8.  Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol.

Authors:  Michael Dagher; Felicia Ruffin; Steven Marshall; Magdalena Taracila; Robert A Bonomo; Rachel Reilly; Vance G Fowler; Joshua T Thaden
Journal:  Open Forum Infect Dis       Date:  2020-05-05       Impact factor: 4.423

9.  Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-world Experience From a Case Series and Review of the Literature.

Authors:  Sandra Zingg; G Jacopo Nicoletti; Sabine Kuster; Milena Junker; Andreas Widmer; Adrian Egli; Vladimira Hinic; Parham Sendi; Manuel Battegay; Veronika Bättig; Nina Khanna; Sarah Tschudin-Sutter
Journal:  Open Forum Infect Dis       Date:  2020-05-21       Impact factor: 3.835

10.  In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria.

Authors:  Shazad Mushtaq; Zahra Sadouki; Anna Vickers; David M Livermore; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.